Val
—
Gro
—
Qua
—
Mom
—
Sta
—
Cap—
P/S7.41
P/E—
Fwd P/E16.16
PEG0.42
52W— – —
RSI—
Target$268.68 (+2.0%)
Beta0.28
Div2.56%
Loading chart…
RSI (14)
Loading patterns…
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
52-Week Range
52W Low
—
52W High
Position in Range
—
RSI (14)
0 · Oversold
RSI 68
Overbought · 100
Signal
Neutral
EMA Price Levels
Volume Analysis
Momentum Dashboard
Trend Strength
Detected Patterns
5Bullish
1Bearish
0Neutral
▲ Inv. Head & Shoulders — Inv. H&S neckline ~$212.10 broken — major bullish reversal
▲ Bull Flag — Breakout after +8% pole — bullish continuation
▲ Bull Flag — Breakout after +11% pole — bullish continuation
▲ Double Bottom — Two lows ~$210.68 — bullish reversal confirmed
▲ Bull Flag — Breakout after +17% pole — bullish continuation
▼ Double Top — Two peaks ~$213.97 — bearish reversal confirmed
View overlays on the price chart via Chart tab → Pattern Overlays.
EPS — History & Forecast
Estimate
Beat
Miss
Forecast
Loading…
Revenue — History & Forecast
Revenue
Forecast
Loading…
EPS Beat Rate
75%
6/8 quarters
Wall Street Consensus
BUY
BuyHoldSell
Price Target Range
$268.68
+2.0% upside
Low $200
—
High $328
Consensus
Current price
Wall Street Analyst Ratings
| Firm | Rating | Change | Action | Date |
|---|---|---|---|---|
| Barclays | Overweight | — | ↔ Maintain | 2026-07-29 |
| Canaccord Genuity | Buy | — | ↔ Maintain | 2026-07-22 |
| Citigroup | Neutral | — | ↔ Maintain | 2026-07-15 |
| UBS | Neutral | — | ↔ Maintain | 2026-07-13 |
| BMO Capital | Outperform | — | ↔ Maintain | 2026-07-13 |
| B of A Securities | Buy | — | ↔ Maintain | 2026-07-10 |
| RBC Capital | Outperform | — | ↔ Maintain | 2026-07-10 |
| Wells Fargo | Overweight | — | ↔ Maintain | 2026-07-10 |
| Guggenheim | Buy | — | ↔ Maintain | 2026-07-09 |
| JP Morgan | Overweight | — | ↔ Maintain | 2026-07-09 |
| Cantor Fitzgerald | Overweight | — | ↔ Maintain | 2026-07-06 |
| Piper Sandler | Overweight | — | ↔ Reiterate | 2026-06-23 |
| Evercore ISI Group | Outperform | — | ↔ Maintain | 2026-05-15 |
| Morgan Stanley | Overweight | — | ↔ Maintain | 2026-04-30 |
| Freedom Broker | Buy | — | ↔ Maintain | 2026-02-17 |
| Wolfe Research | Peer Perform | Outperform → Peer Perform | ▼ Downgrade | 2026-01-08 |
| HSBC | Buy | Hold → Buy | ▲ Upgrade | 2025-12-10 |
Barclays
2026-07-29
Overweight
↔ Maintain
Canaccord Genuity
2026-07-22
Buy
↔ Maintain
Citigroup
2026-07-15
Neutral
↔ Maintain
UBS
2026-07-13
Neutral
↔ Maintain
BMO Capital
2026-07-13
Outperform
↔ Maintain
B of A Securities
2026-07-10
Buy
↔ Maintain
RBC Capital
2026-07-10
Outperform
↔ Maintain
Wells Fargo
2026-07-10
Overweight
↔ Maintain
Guggenheim
2026-07-09
Buy
↔ Maintain
JP Morgan
2026-07-09
Overweight
↔ Maintain
Cantor Fitzgerald
2026-07-06
Overweight
↔ Maintain
Piper Sandler
2026-06-23
Overweight
↔ Reiterate
Evercore ISI Group
2026-05-15
Outperform
↔ Maintain
Morgan Stanley
2026-04-30
Overweight
↔ Maintain
Freedom Broker
2026-02-17
Buy
↔ Maintain
Wolfe Research
2026-01-08
Peer Perform
(from Outperform)
▼ Downgrade
HSBC
2025-12-10
Buy
(from Hold)
▲ Upgrade
Profitability
Gross Margin
72.03%TTM
Op. Margin
32.16%TTM
ROE
N/ATTM
Rev. Growth
12.40%YoY
Free Cash Flow
20.81BTTM
FCF Yield
—TTM
Balance Sheet
Debt / Equity
N/AMRQ
Current Ratio
0.80MRQ
Cash
9.39BMRQ
Total Debt
72.91BMRQ
Net Debt
—MRQ
Income
Div. Yield
2.56%TTM
Annual Rate
6.92Fwd
Payout Ratio
325.98%TTM
Dividend History
Payout Ratio (TTM): 325.98%
| Date | Amount / Share | Yield at Payment |
|---|---|---|
| 2026-07-15 | $1.7300 | 0.71% |
| 2026-04-15 | $1.7300 | 0.84% |
| 2026-01-16 | $1.7300 | 0.82% |
| 2025-10-15 | $1.6400 | 0.74% |
| 2025-07-15 | $1.6400 | 0.91% |
| 2025-04-15 | $1.6400 | 0.96% |
| 2025-01-15 | $1.6400 | 1.00% |
| 2024-10-15 | $1.5500 | 0.86% |
| 2024-07-15 | $1.5500 | 0.98% |
| 2024-04-12 | $1.5500 | 1.03% |
| 2024-01-12 | $1.5500 | 1.04% |
| 2023-10-12 | $1.4800 | 1.10% |
| 2023-07-13 | $1.4800 | 1.23% |
| 2023-04-13 | $1.4800 | 1.02% |
| 2023-01-12 | $1.4800 | 1.10% |
| 2022-10-13 | $1.4100 | 1.13% |
| 2022-07-14 | $1.4100 | 1.08% |
| 2022-04-13 | $1.4100 | 1.03% |
| 2022-01-13 | $1.4100 | 1.24% |
| 2021-10-14 | $1.3000 | 1.42% |
| 2021-07-14 | $1.3000 | 1.33% |
| 2021-04-14 | $1.3000 | 1.49% |
| 2021-01-14 | $1.3000 | 1.43% |
| 2020-10-14 | $1.1800 | 1.71% |
| 2020-07-14 | $1.1800 | 1.50% |
| 2020-04-14 | $1.1800 | 1.83% |
| 2020-01-14 | $1.1800 | 1.73% |
| 2019-10-11 | $1.0700 | 1.91% |
| 2019-07-12 | $1.0700 | 2.03% |
| 2019-04-12 | $1.0700 | 1.79% |
| 2019-01-14 | $1.0700 | 1.73% |
| 2018-10-12 | $0.9600 | 1.47% |
| 2018-07-12 | $0.9600 | 1.41% |
| 2018-04-12 | $0.9600 | 1.48% |
| 2018-01-11 | $0.7100 | 1.02% |
| 2017-10-12 | $0.6400 | 1.01% |
| 2017-07-12 | $0.6400 | 1.29% |
| 2017-04-11 | $0.6400 | 1.46% |
| 2017-01-11 | $0.6400 | 1.55% |
| 2016-10-12 | $0.5700 | 1.39% |
How ABBV Makes Its Money
Cash Flow Breakdown
Quarterly Metrics
| Quarter | Revenue | Rev YoY | Gross Profit | Op. Income | Net Income | Net YoY | Gross % | Op % | Net % |
|---|
Full Key Statistics
Valuation
| Market Cap | 465.20B |
| Enterprise Value | 528.76B |
| Trailing P/E | 128.44 |
| Forward P/E | 16.16 |
| PEG Ratio (5yr) | 0.42 |
| Price/Sales (ttm) | 7.41 |
| Price/Book (mrq) | -69.90 |
| EV/Revenue | 8.42 |
| EV/EBITDA | 17.68 |
Share Statistics
| Avg Vol (3m) | 6.85M |
| Shares Outstanding | 1.77B |
| Float | 1.76B |
| % Held by Insiders | 0.11% |
| % Held by Institutions | 76.90% |
| Short Ratio | 2.42 |
| Short % of Float | 1.42% |
Profitability
| Gross Margin | 72.03% |
| Operating Margin (ttm) | 32.16% |
| Profit Margin | 5.79% |
| Return on Assets (ttm) | 10.03% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 62.82B |
| Revenue Growth (yoy) | 12.40% |
| Gross Profit (ttm) | 45.25B |
| EBITDA | 29.92B |
| Net Income (ttm) | 3.60B |
| Diluted EPS (ttm) | 2.05 |
| EPS Growth (yoy) | -46.20% |
Balance Sheet
| Total Cash (mrq) | 9.39B |
| Total Debt (mrq) | 72.91B |
| Debt / Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.80 |
| Book Value / Share | -3.77 |
| Operating CF (ttm) | 21.22B |
| Free Cash Flow (ttm) | 20.81B |
Trading & Dividends
| Beta (5Y) | 0.28 |
| 50-Day MA | 235.31 |
| 200-Day MA | 224.29 |
| Fwd Dividend Yield | 263.00% |
| Payout Ratio | 325.98% |
Ownership Breakdown
Institutional 76.90%
Insider 0.11%
Public 23.0%
Short Interest
1.42% of float
Low
Institutional 13F Holdings
Famous investors who disclosed a position in ABBV in their latest SEC 13F filing.
Loading…
Insider Transactions
| Date | Insider | Role | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-08 | RAPP EDWARD J | Director | Stock Award(Grant) at price 0.00 per share. | 1,118 | — |
| 2026-05-08 | HART BRETT J | Director | Stock Award(Grant) at price 0.00 per share. | 1,118 | — |
| 2026-05-08 | BURNSIDE WILLIAM H L | Director | Stock Award(Grant) at price 0.00 per share. | 1,118 | — |
| 2026-05-08 | MEYER MELODY B | Director | Stock Award(Grant) at price 0.00 per share. | 1,118 | — |
| 2026-05-08 | ROBERTS REBECCA B. | Director | Stock Award(Grant) at price 0.00 per share. | 1,118 | — |
| 2026-05-08 | DAVIS JENNIFER L | Director | Stock Award(Grant) at price 0.00 per share. | 1,118 | — |
| 2026-05-08 | QUAGGIN SUSAN E | Director | Stock Award(Grant) at price 0.00 per share. | 1,118 | — |
| 2026-05-08 | FREYMAN THOMAS C | Director | Stock Award(Grant) at price 0.00 per share. | 1,118 | — |
| 2026-05-08 | FALK THOMAS J | Director | Stock Award(Grant) at price 0.00 per share. | 1,118 | — |
| 2026-05-08 | AUSTIN ROXANNE SCHUH | Director | Stock Award(Grant) at price 0.00 per share. | 1,118 | — |
| 2026-05-08 | WADDELL FREDERICK H | Director | Stock Award(Grant) at price 0.00 per share. | 1,118 | — |
| 2026-03-04 | PURDUE DAVID RYAN | Officer | Sale at price 233.56 per share. | 5,230 | $1,221,519 |
| 2026-03-02 | SIATIS PERRY C. | General Counsel | Sale at price 233.51 - 235.26 per share. | 18,668 | $4,375,549 |
| 2026-02-25 | SIATIS PERRY C. | General Counsel | Conversion of Exercise of derivative security at price 149.62 - 192.86 per share. | 22,381 | $3,863,458 |
| 2026-02-25 | SIATIS PERRY C. | General Counsel | Sale at price 230.00 per share. | 22,381 | $5,147,630 |
| 2026-02-18 | SALEKI-GERHARDT AZITA | Chief Operating Officer | Stock Award(Grant) at price 0.00 per share. | 36,811 | — |
| 2026-02-18 | MICHAEL ROBERT A. | Chief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 82,439 | — |
| 2026-02-18 | STEWART JEFFREY RYAN | Officer | Stock Award(Grant) at price 0.00 per share. | 53,749 | — |
| 2026-02-18 | DONOGHOE NICHOLAS | Officer | Stock Award(Grant) at price 0.00 per share. | 29,057 | — |
| 2026-02-18 | REENTS SCOTT T. | Chief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 48,838 | — |
| 2026-02-18 | SIATIS PERRY C. | General Counsel | Stock Award(Grant) at price 0.00 per share. | 33,518 | — |
| 2026-02-18 | THAKKAR ROOPAL | Officer | Stock Award(Grant) at price 0.00 per share. | 18,137 | — |
| 2026-02-18 | PURDUE DAVID RYAN | Officer | Stock Award(Grant) at price 0.00 per share. | 6,071 | — |
| 2026-02-18 | CRUM DEMETRIS D | Officer | Stock Award(Grant) at price 0.00 per share. | 2,460 | — |
| 2025-08-12 | SALEKI-GERHARDT AZITA | Chief Operating Officer | Conversion of Exercise of derivative security at price 54.86 per share. | 42,370 | $2,324,418 |
RAPP EDWARD J
Director
Stock Award(Grant) at price 0.00 per share.
2026-05-08
1,118 sh
—
HART BRETT J
Director
Stock Award(Grant) at price 0.00 per share.
2026-05-08
1,118 sh
—
BURNSIDE WILLIAM H L
Director
Stock Award(Grant) at price 0.00 per share.
2026-05-08
1,118 sh
—
MEYER MELODY B
Director
Stock Award(Grant) at price 0.00 per share.
2026-05-08
1,118 sh
—
ROBERTS REBECCA B.
Director
Stock Award(Grant) at price 0.00 per share.
2026-05-08
1,118 sh
—
DAVIS JENNIFER L
Director
Stock Award(Grant) at price 0.00 per share.
2026-05-08
1,118 sh
—
QUAGGIN SUSAN E
Director
Stock Award(Grant) at price 0.00 per share.
2026-05-08
1,118 sh
—
FREYMAN THOMAS C
Director
Stock Award(Grant) at price 0.00 per share.
2026-05-08
1,118 sh
—
FALK THOMAS J
Director
Stock Award(Grant) at price 0.00 per share.
2026-05-08
1,118 sh
—
AUSTIN ROXANNE SCHUH
Director
Stock Award(Grant) at price 0.00 per share.
2026-05-08
1,118 sh
—
WADDELL FREDERICK H
Director
Stock Award(Grant) at price 0.00 per share.
2026-05-08
1,118 sh
—
PURDUE DAVID RYAN
Officer
Sale at price 233.56 per share.
2026-03-04
5,230 sh
$1,221,519
SIATIS PERRY C.
General Counsel
Sale at price 233.51 - 235.26 per share.
2026-03-02
18,668 sh
$4,375,549
SIATIS PERRY C.
General Counsel
Conversion of Exercise of derivative security at price 149.62 - 192.86 per share.
2026-02-25
22,381 sh
$3,863,458
SIATIS PERRY C.
General Counsel
Sale at price 230.00 per share.
2026-02-25
22,381 sh
$5,147,630
SALEKI-GERHARDT AZITA
Chief Operating Officer
Stock Award(Grant) at price 0.00 per share.
2026-02-18
36,811 sh
—
MICHAEL ROBERT A.
Chief Executive Officer
Stock Award(Grant) at price 0.00 per share.
2026-02-18
82,439 sh
—
STEWART JEFFREY RYAN
Officer
Stock Award(Grant) at price 0.00 per share.
2026-02-18
53,749 sh
—
DONOGHOE NICHOLAS
Officer
Stock Award(Grant) at price 0.00 per share.
2026-02-18
29,057 sh
—
REENTS SCOTT T.
Chief Financial Officer
Stock Award(Grant) at price 0.00 per share.
2026-02-18
48,838 sh
—
SIATIS PERRY C.
General Counsel
Stock Award(Grant) at price 0.00 per share.
2026-02-18
33,518 sh
—
THAKKAR ROOPAL
Officer
Stock Award(Grant) at price 0.00 per share.
2026-02-18
18,137 sh
—
PURDUE DAVID RYAN
Officer
Stock Award(Grant) at price 0.00 per share.
2026-02-18
6,071 sh
—
CRUM DEMETRIS D
Officer
Stock Award(Grant) at price 0.00 per share.
2026-02-18
2,460 sh
—
SALEKI-GERHARDT AZITA
Chief Operating Officer
Conversion of Exercise of derivative security at price 54.86 per share.
2025-08-12
42,370 sh
$2,324,418